Claims:

1. A crystalline Form A of 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide or its solvate, hydrate, or solvated hydrate that exhibits an X-ray powder diffraction (XRPD) pattern with characteristic peaks at 4.8±0.1° 2-Theta, 7.1±0.1° 2-Theta, 14.2±0.1° 2-Theta, 16.3±0.1° 2-Theta, 20.1±0.1° 2-Theta.

2. The crystalline Form A of claim 1, wherein the crystalline form further exhibits an X-Ray powder diffraction (XRPD) pattern substantially the same as shown in **Figure 1**.

3. The crystalline Form A of claim 1 or 2, wherein the crystalline form further has unit cell parameters of the following at -173°C:

Crystal system	Orthorhombic				
Space group	*P2(1)2(1)2*	*a*	16.3429(3)Å	α	90°
		b	37.7298(7)Å	β	90°
		c	7.23410(10)Å	γ	90°
V	4460.65(13)Å3				
Z	8				
Dc	1.446g.cm^{-1}				

.

4. The crystalline Form A of any one of claims 1 to 3, wherein the crystalline form further exhibits the same X-ray powder diffraction (XRPD) pattern post storage at 40°C and 75% RH for at least a week.

5. The crystalline Form A of any one of claims 1 to 4, wherein the crystalline form further exhibits a DSC thermogram with an endotherm having an onset temperature at about 108-120ºC and a peak at about 133-135ºC, when a sample of the crystalline Form A is heated at a rate of 2°C per minute.

6. The crystalline Form A of any one of claims 1 to 5, wherein the crystalline form further exhibits a DSC thermogram similar to the one set forth in **Figure 19**, when a sample of the crystalline Form A is heated at a rate of 2°C per minute.

7. The crystalline Form A of any one of claims 1 to 6, wherein the crystalline form was obtained from ethanol.

8. The crystalline Form A of any one of claims 1 to 7, wherein the crystalline form is a solvate.

9. The crystalline Form A of any one of claims 1 to 7, wherein the crystalline form is an ethanol solvate.

10. A pharmaceutical composition comprising 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide and at least one additional ingredient selected from pharmaceutically acceptable carriers, diluents and excipients, in which the 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide in the composition comprises crystalline Form A according to any one of claims 1 to 9.

11. The pharmaceutical composition according to claim 10, wherein the pharmaceutical composition is in a form suitable for oral administration to a human patient.

12. The pharmaceutical composition according to claim 11, wherein the pharmaceutical composition is in an oral solid dosage form.

13. The pharmaceutical composition according to any one of claims 10 to 12, wherein the pharmaceutical composition comprises about 0.5mg to about 1000 mg of crystalline Form A of 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide.

14. Use of a pharmaceutical composition according to any one of claims 10 to 13 in the manufacture of a medicament for the treatment of prostate cancer in a human patient.

15. The use of claim 14, wherein the prostate cancer is hormone sensitive prostate cancer or hormone refractory prostate cancer.